Yonglong Pan

1095 Jiefang Avenue
Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

Interplay among oncogenic pathways governs hepatobiliary lineage decisions in liver cancer.

Interplay among oncogenic pathways governs hepatobiliary lineage decisions in liver cancer.

Journal: iLIVER
Published: February 05, 2026

SU056 potentiates SULF2 antibody in suppressing cholangiocarcinoma metastasis via SULF2-YBX1-CXCR4 signaling axis.

SU056 potentiates SULF2 antibody in suppressing cholangiocarcinoma metastasis via SULF2-YBX1-CXCR4 signaling axis.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: December 19, 2025

Distal-less homeobox 5 transactivated by MYCN contributes to progression of neuroblastoma through AKT signaling pathway.

Distal-less homeobox 5 transactivated by MYCN contributes to progression of neuroblastoma through AKT signaling pathway.

Journal: Cellular signalling
Published: June 27, 2025

Targeting SPAK suppresses progression and averts an immune exhaustive microenvironment in hepatocellular carcinoma.

Targeting SPAK suppresses progression and averts an immune exhaustive microenvironment in hepatocellular carcinoma.

Journal: Nature communications
Published: March 08, 2025

m6A-Mediated TMCO3 Promotes Hepatocellular Carcinoma Progression by Facilitating the Membrane Translocation and Activation of AKT.

m6A-Mediated TMCO3 Promotes Hepatocellular Carcinoma Progression by Facilitating the Membrane Translocation and Activation of AKT.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 07, 2025

Cancer stem cells and niches: challenges in immunotherapy resistance.

Cancer stem cells and niches: challenges in immunotherapy resistance.

Journal: Molecular cancer
Published: December 25, 2024

VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization.

VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization.

Journal: Nature communications
Published: May 02, 2024

Revisiting the chaperonin T-complex protein-1 ring complex in human health and disease: A proteostasis modulator and beyond.

Revisiting the chaperonin T-complex protein-1 ring complex in human health and disease: A proteostasis modulator and beyond.

Journal: Clinical and translational medicine
Published: November 23, 2023

N6-methyladenosine reader YTHDF3-mediated zinc finger protein 41 inhibits hepatocellular carcinoma progression by transcriptional repression of Snail.

N6-methyladenosine reader YTHDF3-mediated zinc finger protein 41 inhibits hepatocellular carcinoma progression by transcriptional repression of Snail.

Journal: MedComm
Published: November 17, 2023

M7G-related tumor immunity: novel insights of RNA modification and potential therapeutic targets.

M7G-related tumor immunity: novel insights of RNA modification and potential therapeutic targets.

Journal: International journal of biological sciences
Published: September 21, 2023

CREB3 suppresses hepatocellular carcinoma progression by depressing AKT signaling through competitively binding with insulin receptor and transcriptionally activating RNA-binding motif protein 38.

CREB3 suppresses hepatocellular carcinoma progression by depressing AKT signaling through competitively binding with insulin receptor and transcriptionally activating RNA-binding motif protein 38.

Journal: MedComm
Published: July 26, 2023

Tubular cell transcriptional intermediary factor 1γ deficiency exacerbates kidney injury-induced tubular cell polyploidy and fibrosis.

Tubular cell transcriptional intermediary factor 1γ deficiency exacerbates kidney injury-induced tubular cell polyploidy and fibrosis.

Journal: Kidney international
Published: October 02, 2022
Showing 1-12 of 26

Last Updated: 09/26/2026